(Q92385655)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

title

Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

10

Özlem Türeci

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

11

Ugur Sahin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

4

Mathias Vormehr

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

9

Sebastian Kreiter

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

1

Fulvia Vascotto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

8

Mustafa Diken

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

3

Kerstin C Walzer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

2

Jutta Petschenka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

author name string

Magdalena Brkic

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Stefan Strobl

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Roman Rösemann

series ordinal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

publication date

19 April 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

page(s)

1601480

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.

29 April 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy.

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1.

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Big opportunities for small molecules in immuno-oncology

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

The multifaceted biology of plasmacytoid dendritic cells

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination.

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Type I interferons in anticancer immunity

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Modes of action of TLR7 agonists in cancer therapy

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Toll-like receptors as therapeutic targets for cancer.

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Accessing the therapeutic potential of immunostimulatory nucleic acids

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Functional role of type I and type II interferons in antiviral defense

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

Accurate identification of experimental pulmonary metastases

17 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6527305

10.1080/2162402X.2019.1601480

17 February 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31143525%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

1 reference